We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- The human immune system: Immune organs
- The immune response against invaders
- The human immune system: Immune cells
- Adaptive and innate immune recognition
- Adaptive and innate immune recognition: Antigen recognition
- The body‘s proprietary gene technology leads to high antibody variability
- Immunotoxicology of human pharmaceuticals: Development of tiered approach
- Validation of tiered testing
- Discussion issue
- Survey results ICH immunotoxicity database 2005
- Immunotoxicology of human pharmaceuticals
- Scope of the guideline
- Overview of the guideline
- Weight-of-evidence review
- Factors to be considered
- First factor to consider: Standard toxicity studies
- Recommended considerations in reviewing standard toxicity study data
- Second factor to consider: Pharmacological properties
- Third factor to consider: Intended patient population
- Fourth factor to consider: Structural similarity
- Fifth factor to consider: Drug Disposition
- Sixth factor to consider: Signs observed clinically
- Selection of assays
- T-cell dependent antibody response (TDAR)
- Evaluation of additional immunotoxicity studies
- Flow diagram for immunotoxicity evaluation (1)
- Flow diagram for immunotoxicity evaluation (2)
- Revision of ICH S8 needed?
- Potential usefulness of immunotoxicogenomics
- Human data on acetaminophen (APAP) (1)
- Human data on acetaminophen (APAP) (2)
- Immunotoxicogenomics
- Immunotoxicity of nanoparticles
- Immunosuppression and carcinogenicity
- Immunostimulation
- Future directions
- Age-related effects on the immune system
- ICH guidance on immunotoxicity testing
- Financial disclosures
Topics Covered
- The human immune system
- Adaptive and innate immunity
- Immunotoxicology of human pharmaceuticals
- ICH immunotoxicity database
- Guideline ICH S8
- Weight-of-evidence review
- Immunotoxicity factors to be considered
- Immunotoxicity evaluation
Talk Citation
van der Laan, J.W. (2026, April 30). ICH S8 immune system toxicity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 30, 2026, from https://doi.org/10.69645/FXMY3615.Export Citation (RIS)
Publication History
- Published on April 30, 2026
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Series: Regulatory ICH Guidelines with Nonclinical Impact
Transcript
Please wait while the transcript is being prepared...
0:00
Dear listeners, I will
give you an explanation of
the ICH S8 topic on the
immune system toxicity.
I'm Jan Willem van der
Laan, and I'm retired from
the Medicines Evaluation
Board in the Netherlands,
where I worked together
with my job in
the National Institute
of Public Health for
more than 40 years on
behalf of the Medicines
Evaluation Board.
In that period, I was
also rapporteur for
the ICH S8 on behalf of the
European Medicines Agency,
which was the very last
in the second phase of
the process finalizing
the document
on behalf of the regulators.
0:47
The outline will be
that I will first
introduce are the most
important aspects
of the human immune system.
Furthermore, some
discussions that we had in
the ICH on preparing
the guideline,
and then the guideline itself.
When the guideline
was finished in 2008,
we recently discussed
the possibility of the revision,
which is my own part,
and then we came
to the conclusion.
1:17
The human immune system
is well distributed
over the body.
You see the main
important organs
such as the thymus, the spleen,
and the bone marrow, as well as
the additional lymph nodes in
the tonsils spread
over the body.
That makes the system
very fluid, and
the cells are traveling in the
body among these elements.